ClinicalTrials.gg
CompletedNCT02030600SWITCH 2Updated May 10, 2019Results posted

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 166 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-10.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
721
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
8th of 70
721 · median 384
Started
2014
with 2 others
Phase 3
49 of 70
2 open now
Registered
40th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 3 that started in 2014, is one of 49 in phase 3, and was the 40th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar) with or without OADs (oral anti-diabetic drugs) excluding SUs (sulfonylureas)/glinides in subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 721 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Male or female, age at least 18 years at the time of signing - Subjects fulfilling at least one of the below criteria: a) Experienced at least one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes Association) definition, April 2013), b) Moderate chronic renal failure, defined as 30 - 59 mL/min/1.73 m\^2 per CKD-Epi (Chronic Kidney Disease Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1 (screening) - Type 2 diabetes mellitus (diagnosed clinically) for at least 26 weeks prior to Visit 1 - Current treatment with any basal insulin (OD or BID) ± any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor, thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 For subjects on BID the total daily dose should be below 75 units - (glycosylated ) below or equal to 9.5 % by central laboratory analysis - (body mass index) below or equal to 45 kg/m\^2 Exclusion Criteria: - Treatment with a bolus insulin separately or contained in an insulin mix product within the last 26 weeks prior to Visit 1 - Use of any other anti-diabetic agent(s) than those stated in the inclusion criteria within the last 26 weeks prior to Visit 1

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
721 participants (actual)

Study arms

  • Experimental
    IDeg OD ± OADs followed by IGlar OD ± OADs

    The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.

    Drug: insulin degludec · Drug: insulin glargine

  • Active comparator
    IGlar OD ± OADs followed by IDeg OD ± OADs

    The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.

    Drug: insulin degludec · Drug: insulin glargine

Interventions

  • Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

  • Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

07

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period

    Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

    Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)

Secondary outcomes

  1. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period

    Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

    Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)

  2. Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period

    Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)

  3. Incidence of Treatment Emergent Adverse Events

    Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

    Time frame: During 32 weeks of treatment for each treatment period

  4. Change From Baseline in HbA1c (Glycosylated Haemoglobin)

    Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c value was considered as baseline for calculating change from baseline in HbA1c at week 64.

    Time frame: Week 32, Week 64

  5. FPG (Fasting Plasma Glucose)

    Fasting plasma glucose values at week 32 and week 64.

    Time frame: week 32, week 64

08

Results

Posted Jan 30, 2017

Participant flow

The trial was conducted at 152 sites in the United States.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
Started361360
Exposed356357
Completed308315
Not completed5345
Withdrew: Adverse event57
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up113
Withdrew: Protocol violation2217
Withdrew: Withdrawal by subject1317
Withdrew: Casebook unsigned10
Withdrew: Unclassified10
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
Started308315
Completed283297
Not completed2518
Withdrew: Adverse event44
Withdrew: Lack of efficacy21
Withdrew: Lost to follow-up42
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject139
Withdrew: Unclassified10

Outcome measures

PrimaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period

Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

Time frame:
After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Reported as:
Number · events
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period
eventsInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period353496
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · Poisson · p = <0.0001 · Treatment ratio: 0.70 · 95% CI 0.61 to 0.80Superiority was considered confirmed if the 95% confidence interval for the rate ratio (IDeg/IGlar) was entirely below 1.0.
SecondaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period

Severe or BG confirmed symptomatic nocturnal hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia and with time of onset between 00:01 and 05.59 a.m., both inclusive. Treatment emergent hypoglycaemic episode was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

Time frame:
After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Reported as:
Number · events
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period
eventsInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Nocturnal Hypoglycaemic Episode During the Maintenance Period105175
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · Poisson · p = <0.0001 · Treatment ratio: 0.58 · 95% CI 0.46 to 0.74Superiority was considered confirmed if the 95% confidence interval for the rate ratio (IDeg/IGlar) was entirely below 1.0.
SecondaryProportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period

Percentage of subjects who experienced one or more severe hypoglycaemic episodes during the maintenance period. Severe hypoglycaemia (according to the American Diabetes Association 2013 definition): A hypoglycaemic episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose values may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64)
Reported as:
Number · percentage of subjects
Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period
percentage of subjectsInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Proportion of Subjects With One or More Severe Hypoglycaemic Episodes During the Maintenance Period1.62.4
Statistical analysis
  • Insulin Degludec (IDeg) vs Insulin Glargine (IGlar) · McNemar · p = 0.3458 (Superiority was confirmed if the p-value was less than 0.025.)
SecondaryIncidence of Treatment Emergent Adverse Events

Treatment emergent adverse event was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.

Time frame:
During 32 weeks of treatment for each treatment period
Reported as:
Number · events
Incidence of Treatment Emergent Adverse Events
eventsInsulin Degludec (IDeg)Insulin Glargine (IGlar)
Incidence of Treatment Emergent Adverse Events12931381
SecondaryChange From Baseline in HbA1c (Glycosylated Haemoglobin)

Change from baseline in HbA1c (glycosylated haemoglobin) at week 32 (treatment period 1) and at week 64 (treatment period 2). Week 32 HbA1c value was considered as baseline for calculating change from baseline in HbA1c at week 64.

Time frame:
Week 32, Week 64
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
percentage of glycosylated haemoglobinInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
week 32 (n=308, 313)-0.49 ± 0.99-0.58 ± 1.02
week 64 (n=295, 301)0.03 ± 0.750.10 ± 0.83
Statistical analysis
  • Insulin Degludec/Insulin Glargine (IDeg/IGlar) vs Insulin Glargine/Insulin Degludec (IGlar/IDeg) · Treatment contrast: 0.09 · 95% CI -0.04 to 0.23
  • Insulin Degludec/Insulin Glargine (IDeg/IGlar) vs Insulin Glargine/Insulin Degludec (IGlar/IDeg) · Treatment contrast: 0.06 · 95% CI -0.07 to 0.18
SecondaryFPG (Fasting Plasma Glucose)

Fasting plasma glucose values at week 32 and week 64.

Time frame:
week 32, week 64
Reported as:
Mean · mg/dL
FPG (Fasting Plasma Glucose)
mg/dLInsulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)
week 32 (n=307, 311)107.33 ± 41.72106.96 ± 39.81
week 64 (n=293, 302)114.07 ± 51.91107.55 ± 51.30

Adverse events

Collected over From the first day of exposure to randomised treatment and no later than the last day of randomised treatment (64 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec (IDeg)—64/671 (9.5%)93/671 (13.9%)
Insulin Glargine (IGlar)—65/665 (9.8%)77/665 (11.6%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
HypoglycaemiaMetabolism and nutrition disorders2/6719/665
Angina pectorisCardiac disorders1/6714/665
SepsisInfections and infestations1/6714/665
Coronary artery diseaseCardiac disorders2/6713/665
Non-cardiac chest painGeneral disorders3/6713/665
Angina unstableCardiac disorders0/6712/665
AsthmaRespiratory, thoracic and mediastinal disorders1/6712/665
Cardiac failure congestiveCardiac disorders1/6712/665
Renal cystRenal and urinary disorders0/6712/665
Transient ischaemic attackNervous system disorders0/6712/665
Most frequent other events
Most frequent other events
EventInsulin Degludec (IDeg)Insulin Glargine (IGlar)
NasopharyngitisInfections and infestations50/67141/665
Upper respiratory tract infectionInfections and infestations44/67137/665

Baseline characteristics

Full analysis set included all randomised subjects. One subject was excluded from the analysis due to unsigned casebook.

Age, Continuous
Age, Continuous(years)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean61.5 ± 10.761.2 ± 10.361.4 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Female169169338
Male191191382
Glycosylated haemoglobin
Glycosylated haemoglobin(percentage of glycosylated haemoglobin)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean7.6 ± 1.17.6 ± 1.17.6 ± 1.1
Fasting plasma glucose
Fasting plasma glucose(mg/dL)Insulin Degludec/Insulin Glargine (IDeg/IGlar)Insulin Glargine/Insulin Degludec (IGlar/IDeg)Total
Mean139.2 ± 53.5134.9 ± 51.6137.0 ± 52.6
09

Study locations

166 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35215-7502, United States
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35216, United States
  • Novo Nordisk Investigational Site
    Haleyville, Alabama 35565-1719, United States
  • Novo Nordisk Investigational Site
    Montgomery, Alabama 36106, United States
  • Novo Nordisk Investigational Site
    Tuscumbia, Alabama 35674, United States
  • Novo Nordisk Investigational Site
    Chandler, Arizona 85224, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85050, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85704, United States
  • Novo Nordisk Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novo Nordisk Investigational Site
    Costa Mesa, California 92626, United States
  • Novo Nordisk Investigational Site
    Downey, California 90242, United States
  • Novo Nordisk Investigational Site
    El Cajon, California 92020, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93702, United States
  • Novo Nordisk Investigational Site
    Fresno, California 93720, United States
  • Novo Nordisk Investigational Site
    Hawaiian Gardens, California 90716, United States
  • Novo Nordisk Investigational Site
    Huntington Park, California 90255, United States
  • Novo Nordisk Investigational Site
    Lincoln, California 95648, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90807, United States
  • Novo Nordisk Investigational Site
    Montclair, California 91763, United States
  • Novo Nordisk Investigational Site
    North Hollywood, California 91606, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Pomona, California 91766-2007, United States
  • Novo Nordisk Investigational Site
    Poway, California 92064, United States
  • Novo Nordisk Investigational Site
    Rancho Cucamonga, California 91730-3063, United States
  • Novo Nordisk Investigational Site
    Rialto, California 92376, United States
  • Novo Nordisk Investigational Site
    Roseville, California 95661, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92111, United States
  • Novo Nordisk Investigational Site
    Santa Monica, California 90404, United States
  • Novo Nordisk Investigational Site
    Tarzana, California 91356-3551, United States
  • Novo Nordisk Investigational Site
    Torrance, California 90502, United States
  • Novo Nordisk Investigational Site
    Tustin, California 92780, United States
  • Novo Nordisk Investigational Site
    Colorado Springs, Colorado 80910, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Newark, Delaware 19713, United States
  • Novo Nordisk Investigational Site
    Bradenton, Florida 34201, United States
  • Novo Nordisk Investigational Site
    Chiefland, Florida 32626, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33756, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Cooper City, Florida 33024, United States
  • Novo Nordisk Investigational Site
    Doral, Florida 33166, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33012, United States
  • Novo Nordisk Investigational Site
    Hialeah, Florida 33013, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32204, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32216, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32256, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32277, United States
  • Novo Nordisk Investigational Site
    Miami Springs, Florida 33166, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33130, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33156, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33165, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33174, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33175, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33186, United States
  • Novo Nordisk Investigational Site
    Miramar, Florida 33027, United States
  • Novo Nordisk Investigational Site
    New Port Richey, Florida 34652, United States
  • Novo Nordisk Investigational Site
    Ocala, Florida 34470, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32801, United States
  • Novo Nordisk Investigational Site
    Panama City, Florida 32401, United States
  • Novo Nordisk Investigational Site
    Pembroke Pines, Florida 33026, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33607, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33619, United States
  • Novo Nordisk Investigational Site
    Perry, Georgia 31069, United States
  • Novo Nordisk Investigational Site
    Champaign, Illinois 61821, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60611, United States
  • Novo Nordisk Investigational Site
    Evansville, Indiana 47714, United States
  • Novo Nordisk Investigational Site
    Muncie, Indiana 47304, United States
  • Novo Nordisk Investigational Site
    West Des Moines, Iowa 50265, United States
  • Novo Nordisk Investigational Site
    Lenexa, Kansas 66219, United States
  • Novo Nordisk Investigational Site
    Newton, Kansas 67114, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40502, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Louisville, Kentucky 40213, United States
  • Novo Nordisk Investigational Site
    Paducah, Kentucky 42003, United States
  • Novo Nordisk Investigational Site
    New Orleans, Louisiana 70119, United States
  • Novo Nordisk Investigational Site
    Shreveport, Louisiana 71105, United States
  • Novo Nordisk Investigational Site
    Brockton, Massachusetts 02301, United States
  • Novo Nordisk Investigational Site
    Kalamazoo, Michigan 49009, United States
  • Novo Nordisk Investigational Site
    Olive Branch, Mississippi 38654-3573, United States
  • Novo Nordisk Investigational Site
    Florissant, Missouri 63031, United States
  • Novo Nordisk Investigational Site
    Jefferson City, Missouri 65109, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64106, United States
  • Novo Nordisk Investigational Site
    Henderson, Nevada 89052-2649, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89148, United States
  • Novo Nordisk Investigational Site
    Newington, New Hampshire 03801, United States
  • Novo Nordisk Investigational Site
    Morganville, New Jersey 07751, United States
  • Novo Nordisk Investigational Site
    Teaneck, New Jersey 07666, United States
  • Novo Nordisk Investigational Site
    Albuquerque, New Mexico 87102, United States
  • Novo Nordisk Investigational Site
    Albany, New York 12208, United States
  • Novo Nordisk Investigational Site
    Jackson Heights, New York 11372, United States
  • Novo Nordisk Investigational Site
    New Windsor, New York 12553, United States
  • Novo Nordisk Investigational Site
    Northport, New York 11768, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    Charlotte, North Carolina 28277, United States
  • Novo Nordisk Investigational Site
    Morganton, North Carolina 28655, United States
  • Novo Nordisk Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Novo Nordisk Investigational Site
    Delaware, Ohio 43015, United States
  • Novo Nordisk Investigational Site
    Franklin, Ohio 45005, United States
  • Novo Nordisk Investigational Site
    Toledo, Ohio 43614, United States
  • Novo Nordisk Investigational Site
    Oklahoma City, Oklahoma 73103, United States

Showing the first 100 of 166 sites across 2 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Chaykin L, Bhargava A, de la Rosa R, Wysham CH, Norgard Troelsen L, Ostoft SH, Philis-Tsimikas A. Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial. Clin Diabetes. 2019 Jan;37(1):73-81. doi: 10.2337/cd18-0016. PubMed 30705500 ↗
  • Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 4;318(1):45-56. doi: 10.1001/jama.2017.7117. PubMed 28672317 ↗
  • Evans M, Mehta R, Gundgaard J, Chubb B. Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting. Diabetes Ther. 2018 Oct;9(5):1919-1930. doi: 10.1007/s13300-018-0478-1. Epub 2018 Aug 10. PubMed 30097995 ↗
  • DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26. PubMed 30362250 ↗
  • Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes Obes Metab. 2019 Jul;21(7):1634-1641. doi: 10.1111/dom.13708. Epub 2019 Apr 15. PubMed 30891886 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Dec 2015, 22 months.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2014
First posted
Jan 8, 2014
StartActual
Jan 6, 2014
Primary completionActual
Dec 4, 2015
CompletionActual
Dec 4, 2015
Results first posted
Jan 30, 2017
Last update
May 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02030600
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 8, 2014
Start date
Jan 6, 2014
Primary completion
Dec 4, 2015
Completion
Dec 4, 2015
Results posted
Jan 30, 2017
Last update
May 10, 2019

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine

Start the discussion